We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

186 hedge funds and large institutions have $1.18B invested in Arcutis Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 59 increasing their positions, 55 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

158% more call options, than puts

Call options by funds: $7.03M | Put options by funds: $2.73M

62% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 29

11% more funds holding

Funds holding: 168 → 186 (+18)

7% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 55

0.57% more ownership

Funds ownership: 108.71% → 109.28% (+0.57%)

5% less capital invested

Capital invested by funds: $1.24B → $1.18B (-$61.9M)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
186
Holders Change
+18
Holders Change %
+10.71%
% of All Funds
2.69%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
47
Increased
59
Reduced
55
Closed
29
Calls
$7.03M
Puts
$2.73M
Net Calls
+$4.3M
Net Calls Change
+$8.98M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$20.9M
2
SCM
Suvretta Capital Management
New York
+$19.2M
3
BlackRock
BlackRock
New York
+$17.8M
4
CS
Candriam SCA
Luxembourg
+$11.8M
5
Citadel Advisors
Citadel Advisors
Florida
+$9.21M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$33M
2
FCM
Farallon Capital Management
California
-$15.9M
3
B
Braidwell
Connecticut
-$12.9M
4
SC
Stempoint Capital
New York
-$11.2M
5
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$8.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
Zurich Cantonal Bank
126
Zurich Cantonal Bank
Switzerland
$174K +$170K +18,762 New
Pictet Asset Management
127
Pictet Asset Management
Switzerland
$173K +$168K +18,557 New
Principal Financial Group
128
Principal Financial Group
Iowa
$173K -$5.16K -570 -3%
CB
129
Commerce Bank
Missouri
$165K – – –
ProShare Advisors
130
ProShare Advisors
Maryland
$165K -$29.4K -3,251 -15%
BG
131
Bellevue Group
Switzerland
$163K +$158K +17,500 New
SSA
132
Schonfeld Strategic Advisors
New York
$150K +$146K +16,174 New
EFM
133
E Fund Management
China
$147K -$209K -23,107 -59%
HSBC Holdings
134
HSBC Holdings
United Kingdom
$131K -$4.45M -492,187 -97%
CUAMC
135
China Universal Asset Management Company
China
$126K -$45.3K -5,013 -27%
Royal Bank of Canada
136
Royal Bank of Canada
Ontario, Canada
$118K +$86.4K +9,558 +309%
DC
137
Diametric Capital
Massachusetts
$116K +$112K +12,426 New
ET
138
Entropy Technologies
New York
$109K +$106K +11,772 New
Victory Capital Management
139
Victory Capital Management
Texas
$109K -$4.4K -487 -4%
EAM
140
Erste Asset Management
Austria
$105K – – –
IWC
141
Integrated Wealth Concepts
Massachusetts
$104K +$452 +50 +0.4%
OAC
142
OMERS Administration Corp
Ontario, Canada
$100K +$97.7K +10,800 New
Mariner
143
Mariner
Kansas
$99.8K -$64K -7,079 -40%
AG
144
Algert Global
California
$97K +$94.2K +10,415 New
AIP
145
Ameritas Investment Partners
Nebraska
$96.8K +$22.9K +2,537 +32%
PNC Financial Services Group
146
PNC Financial Services Group
Pennsylvania
$90.5K -$298 -33 -0.3%
VEA
147
Virtus ETF Advisers
New York
$90.1K +$87.6K +9,692 New
Canada Life
148
Canada Life
Manitoba, Canada
$76K +$74.5K +8,233 New
CP
149
Castleview Partners
Texas
$75.5K +$73.4K +8,113 New
EC
150
EntryPoint Capital
New York
$61.1K +$59.4K +6,572 New
4 5
6
7 8

ARQT Hedge Fund Activity: Q2 2024 in Review

186 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2024, worth a combined $1.18B — down 5% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new ARQT positions and 29 closed out — a net gain of 18 holders — while 59 added to existing stakes and 55 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $20.9M. The largest seller was State Street, cutting an estimated $33M.

  • 186 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2024, up from 168 in Q1 2024.
  • Funds reported $1.18B of Arcutis Biotherapeutics stock for Q2 2024, down 5% quarter-over-quarter.
  • 47 funds opened new Arcutis Biotherapeutics positions in Q2 2024 and 29 closed out, a net change of +18 holders.
  • The largest Arcutis Biotherapeutics buyer in Q2 2024 was Rubric Capital Management (New York), an estimated $20.9M added.
  • The largest Arcutis Biotherapeutics seller in Q2 2024 was State Street, an estimated $33M sold.

Based on aggregated 13F filings for Q2 2024.